AI PRICE FORECAST
BSX Stock Forecast & AI Price Prediction
Boston Scientific · Healthcare · Medical Devices
BSX live signal snapshot
Shares of BSX were last at $45.13, up 0.96% on the day, trading 57.3% below its 52-week high of $105.65 and 14.1% above its 52-week low of $39.57. The model's verdict for BSX right now: HOLD (70% confidence). The technical signals aren't aligned enough for a directional call yet. The short-term averages are tangled, giving no clean trend signal either way. Its one-month projection is about $46.31, a 2.6% move from the last price.
BSX's 14-day RSI is 48.2 — a neutral zone, with no decisive edge for bulls or bears. The MACD indicator sits over its signal line, and the histogram reading of 0.11 shows buying pressure building. Its 50-day average ($44.15) remains 19.2% below the 200-day ($54.63), the pattern chartists call a death cross.
28 Wall Street analysts covering BSX put the average price target at $49.60 (range $41.00–$60.00), implying 9.9% upside from the current price. The current recommendation trend leans bullish: 19 Buy/Strong Buy ratings vs 0 Sell/Strong Sell (and 12 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive BSX dashboard for numbers updated throughout today's session.
About Boston Scientific
Boston Scientific Corporation (BSX) is a medical devices company in the healthcare sector, headquartered in Marlborough, MA, United States. Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It has a market value of about $65.4 billion and roughly 59,000 full-time employees. With a beta of 0.58, the stock has historically moved less than the overall market.
BSX performance vs. the market
Year to date, BSX has lost 52.7%, behind the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has lost 55.3%, 66.8 points worse than the S&P 500. The direction has flipped lately — +4.2% over the past month versus −12.7% across three.
| Period | BSX | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +4.2% | +11.4% | −2.3% |
| 3 months | −12.7% | +12.2% | −2.3% |
| Year to date | −52.7% | +22.1% | +11.4% |
| 1 year | −55.3% | +28.3% | +11.5% |
Boston Scientific financials at a glance
Boston Scientific's most recent quarter (ended Sep 30, 2026) brought in $5.1 billion of revenue and net income of $582 million (a 11.3% net margin). Revenue was up 1.4% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 19.0 on trailing earnings of $2.37 per share. Trailing free cash flow was $2.5 billion, and total debt equals 46% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $5.1B | $582M |
| Jun 30, 2026 | $5.4B | $907M |
| Mar 31, 2026 | $5.2B | $1.3B |
| Dec 31, 2025 | $5.3B | $672M |
BSX vs. its peers
BSX's −52.7% this year ranks ahead of 0 of the 5 big healthcare names below. The strongest of the group this year is Edwards Lifesciences (EW, +24.1%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Boston Scientific (BSX) | $45.13 | −52.7% | 19.0 | HOLD |
| Abbott Laboratories (ABT) | $109.29 | −12.8% | 40.8 | HOLD |
| Medtronic (MDT) | $101.61 | +5.8% | 25.0 | HOLD |
| Stryker (SYK) | $318.79 | −9.3% | 33.9 | HOLD |
| Edwards Lifesciences (EW) | $105.81 | +24.1% | 61.5 | BUY |
| GE HealthCare Technologies (GEHC) | $82.60 | +0.7% | 17.5 | BUY |
BSX stock: common questions
What is the BSX stock price target?
28 Wall Street analysts put the average 12-month target at $49.60, in a range of $41.00–$60.00, versus a recent price of $45.13. Stock Pulse 247's model projects about $46.31 over the next month.
Is BSX a buy right now?
Our AI model currently rates BSX a HOLD at 70% confidence. Among analysts, 19 rate it Buy or Strong Buy, 12 Hold and 0 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has BSX stock performed this year?
Year to date, BSX has lost 52.7%, behind the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has lost 55.3%, 66.8 points worse than the S&P 500. The direction has flipped lately — +4.2% over the past month versus −12.7% across three.
What is BSX's 52-week high and low?
BSX has traded between $39.57 and $105.65 over the past 52 weeks; at $45.13 it is 57.3% below its 52-week high of $105.65 and 14.1% above its 52-week low of $39.57.
What sector is BSX in, and who are its peers?
BSX is in the healthcare sector (medical devices). Its largest peers on Stock Pulse 247 include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Edwards Lifesciences (EW).
How accurate is the BSX forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines BSX's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.